San Francisco Bay Area biotech stories.
Thursday, April 26, 2012
Transcept seeks $37M from stock offering
Transcept Pharmaceuticals Inc. would use some of the $37.6 million
it hopes to net from a public stock offering to sell its FDA-approved middle-of-the-night sleep drug and to move forward with a drug for obsessive compulsive disorder. Transcept priced the offering of 4.5 million shares at $9 per share.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)